Serological immunoreactivity against colon cancer proteome varies upon disease progression.
Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.
De Monte
Lucia
L
Proteome Biochemistry, Tumor Immunology, Mass Spectrometry, Pathology, Surgery, Experimental Immunology, Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy.
Sanvito
Francesca
F
Olivieri
Stefano
S
Viganò
Fiammetta
F
Doglioni
Claudio
C
Frasson
Matteo
M
Braga
Marco
M
Bachi
Angela
A
Dellabona
Paolo
P
Protti
Maria Pia
MP
Alessio
Massimo
M
D000230:Adenocarcinoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D019073:HT29 Cells; D006801:Humans; D008297:Male; D008875:Middle Aged; D020543:Proteome / Q000276:immunology* / Q000378:metabolism; D040901:Proteomics
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D020543:Proteome